# PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

> **NCT05232006** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 12 (estimated)

## Conditions studied

- Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05232006
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-05
- **Primary completion:** 2024-09
- **Final completion:** 2030-05
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05232006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05232006, "PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05232006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*